Marvin A. Konstam

Marvin A. Konstam's AcademicInfluence.com Rankings

Marvin A. Konstam

Philosophy

#6231

World Rank

#9233

Historical Rank

Logic

#3414

World Rank

#4567

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Marvin A. Konstam's Degrees

Doctorate Medicine Harvard University

Why Is Marvin A. Konstam Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Marvin A. Konstam's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult—Summary Article (2005) (5001)
Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. (2005) (2544)
Forecasting the Impact of Heart Failure in the United States: A Policy Statement From the American Heart Association (2013) (2088)
Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE II (2000) (1955)
2009 Focused Update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults (2009) (1575)
Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. (2007) (1532)
Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. (2007) (818)
Acute Heart Failure Syndromes: Current State and Framework for Future Research (2005) (731)
Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. (2001) (725)
Executive summary: HFSA 2006 Comprehensive Heart Failure Practice Guideline. (2006) (723)
Comparison of Omapatrilat and Enalapril in Patients With Chronic Heart Failure: The Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE) (2002) (630)
Left ventricular remodeling in heart failure: current concepts in clinical significance and assessment. (2011) (598)
Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLVD Investigators. (1992) (545)
Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial (2009) (525)
Heart failure: evaluation and care of patients with left ventricular systolic dysfunction. (1995) (506)
Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. (2003) (486)
Predicting recovery of severe regional ventricular dysfunction. Comparison of resting scintigraphy with 201Tl and 99mTc-sestamibi. (1994) (433)
ACC/AHA Clinical Performance Measures for Adults with Chronic Heart Failure: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Heart Failure Clinical Performance Measures): endorsed by the Heart Failure Society (2005) (432)
Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial. (2013) (417)
Effects of the Angiotensin Converting Enzyme Inhibitor Enalapril on the Long‐term: Progression of Left Ventricular Dysfunction in Patients With Heart Failure (1992) (408)
Consensus recommendations for the management of chronic heart failure: Introduction (1999) (391)
Clinical course and predictive value of congestion during hospitalization in patients admitted for worsening signs and symptoms of heart failure with reduced ejection fraction: findings from the EVEREST trial. (2013) (388)
Baseline quality of life as a predictor of mortality and hospitalization in 5,025 patients with congestive heart failure. SOLVD Investigations. Studies of Left Ventricular Dysfunction Investigators. (1996) (376)
Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: a meta-analytic approach. (2010) (367)
Evaluation and Management of Right-Sided Heart Failure: A Scientific Statement From the American Heart Association (2018) (349)
Heart Failure Society of America (HFSA) practice guidelines. HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction--pharmacological approaches. (1999) (340)
Decreased lymphocyte beta-adrenergic-receptor density in patients with heart failure and tolerance to the beta-adrenergic agonist pirbuterol. (1981) (336)
Acute Hemodynamic Effects of Conivaptan, a Dual V1A and V2 Vasopressin Receptor Antagonist, in Patients With Advanced Heart Failure (2001) (331)
Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial (2004) (329)
HFSA 2006 comprehensive heart failure practice guideline (2006) (329)
Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure. Lack of benefit compared with placebo. Enoximone Multicenter Trial Group. (1990) (317)
Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction. SOLVD Investigators. (1996) (315)
Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dilatation in patients with asymptomatic systolic dysfunction. SOLVD (Studies of Left Ventricular Dysfunction) Investigators. (1993) (304)
Cardiovascular Thrombotic Events in Controlled, Clinical Trials of Rofecoxib (2001) (260)
Antiplatelet agents and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction (SOLVD) trial. (1998) (255)
Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: results from Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) program. (2010) (231)
Warfarin anticoagulation and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction. (1998) (223)
Management of heart failure. III. The role of revascularization in the treatment of patients with moderate or severe left ventricular systolic dysfunction. (1994) (208)
The problem of decompensated heart failure: nomenclature, classification, and risk stratification. (2003) (199)
The excimer laser: gross, light microscopic and ultrastructural analysis of potential advantages for use in laser therapy of cardiovascular disease. (1985) (198)
Long-term oral administration of amrinone for congestive heart failure: lack of efficacy in a multicenter controlled trial. (1985) (197)
Comparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart failure: results of a meta-analysis. (2001) (194)
Cost-effectiveness of screening with B-type natriuretic peptide to identify patients with reduced left ventricular ejection fraction. (2004) (191)
Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST). (2005) (187)
Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document (2013) (183)
Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) program. (2008) (178)
Clinical implications of QRS duration in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction. (2008) (178)
Evaluating quality of care for patients with heart failure. (2000) (171)
The continuous heart failure spectrum: moving beyond an ejection fraction classification. (2019) (170)
Effects of Xanthine Oxidase Inhibition in Hyperuricemic Heart Failure Patients: The Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients (EXACT-HF) Study (2015) (166)
Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international, multicenter, randomized, placebo-controlled trial. (2008) (165)
Association between diabetes mellitus and post‐discharge outcomes in patients hospitalized with heart failure: findings from the EVEREST trial (2013) (162)
Efficacy and Safety of Spironolactone in Acute Heart Failure: The ATHENA-HF Randomized Clinical Trial (2017) (161)
Clinical course and predictive value of liver function tests in patients hospitalized for worsening heart failure with reduced ejection fraction: an analysis of the EVEREST trial (2012) (160)
Randomized, Controlled Evaluation of Short- and Long-Term Benefits of Heart Failure Disease Management Within a Diverse Provider Network: The SPAN-CHF Trial (2004) (160)
Ejection Fraction: Misunderstood and Overrated (Changing the Paradigm in Categorizing Heart Failure) (2017) (159)
Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction. (2007) (153)
Vasopressin v(2) receptor blockade with tolvaptan versus fluid restriction in the treatment of hyponatremia. (2006) (144)
Acute heart failure syndromes in patients with coronary artery disease early assessment and treatment. (2009) (142)
Clinical Trials of Pharmacological Therapies in Acute Heart Failure Syndromes: Lessons Learned and Directions Forward (2010) (141)
Ventricular remodeling in a mouse model of myocardial infarction. (1998) (140)
Comparison of ejection fraction and Goldman risk factor analysis to dipyridamole-thallium 201 studies in the evaluation of cardiac morbidity after aortic aneurysm surgery. (1990) (138)
Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with tolvaptan. (2013) (138)
Key issues in end point selection for heart failure trials: composite end points. (2005) (129)
Identifying Patients Hospitalized With Heart Failure at Risk for Unfavorable Future Quality of Life (2011) (129)
Changes in renal function during hospitalization and soon after discharge in patients admitted for worsening heart failure in the placebo group of the EVEREST trial. (2011) (127)
Changes in Pulmonary Blood Flow Affect Vascular Response to Chronic Hypoxia in Rats (1983) (127)
Haemoconcentration, renal function, and post‐discharge outcomes among patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial (2013) (124)
Randomized, Double-Blind, Multicenter, Placebo-Controlled Study Evaluating the Effect of Aldosterone Antagonism With Eplerenone on Ventricular Remodeling in Patients With Mild-to-Moderate Heart Failure and Left Ventricular Systolic Dysfunction (2010) (124)
Research priorities in hypertrophic cardiomyopathy: report of a Working Group of the National Heart, Lung, and Blood Institute. (2010) (123)
Effects of the Angiotensin Converting Enzyme Inhibitor Enalapril on the Long‐term Progression of Left Ventricular Dilatation in Patients With Asymptomatic Systolic Dysfunction (1993) (117)
Short-Term Effects of Tolvaptan in Patients With Acute Heart Failure and Volume Overload. (2017) (115)
Effect of long-term enalapril therapy on neurohormones in patients with left ventricular dysfunction (1995) (115)
Treatment of calcific aortic stenosis by balloon valvuloplasty. (1987) (114)
Progression of left ventricular dysfunction secondary to coronary artery disease, sustained neurohormonal activation and effects of ibopamine therapy during long-term therapy with angiotensin-converting enzyme inhibitor. (1994) (112)
Progress in heart failure Management? Lessons from the real world. (2000) (110)
A comprehensive, longitudinal description of the in-hospital and post-discharge clinical, laboratory, and neurohormonal course of patients with heart failure who die or are re-hospitalized within 90 days: analysis from the EVEREST trial (2012) (109)
Ventricular remodeling in heart failure: a credible surrogate endpoint. (2003) (108)
The effect of ventricular assist devices on post-transplant mortality an analysis of the United network for organ sharing thoracic registry. (2009) (108)
Randomized,multicenter,double-blind,placebo-controlled evaluation of amlodipine in patients with mild-to-moderate heart failure (1991) (107)
Arginine Vasopressin Antagonists for the Treatment of Heart Failure and Hyponatremia (2008) (102)
Heart Failure With Preserved Ejection Fraction Expert Panel Report: Current Controversies and Implications for Clinical Trials. (2018) (101)
Heart Failure: Pathophysiology, Molecular Biology, and Clinical Management (2000) (98)
Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure. (2001) (97)
Effects of losartan versus captopril on mortality in patients with symptomatic heart failure: rationale, design, and baseline characteristics of patients in the Losartan Heart Failure Survival Study--ELITE II. (1999) (94)
A multicenter randomized controlled evaluation of automated home monitoring and telephonic disease management in patients recently hospitalized for congestive heart failure: the SPAN-CHF II trial. (2010) (92)
Relation between left ventricular remodeling and clinical outcomes in heart failure patients with left ventricular systolic dysfunction. (2002) (91)
Measuring and improving quality of care: a report from the American Heart Association/American College of Cardiology First Scientific Forum on Assessment of Healthcare Quality in Cardiovascular Disease and Stroke. (2000) (89)
Critical elements of clinical follow‐up after hospital discharge for heart failure: insights from the EVEREST trial (2010) (88)
Effects of a percutaneous mechanical circulatory support device for medically refractory right ventricular failure. (2011) (87)
Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: insights from the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) trial. (2013) (86)
A multicenter, randomized, double-blind, placebo-controlled study of tolvaptan monotherapy compared to furosemide and the combination of tolvaptan and furosemide in patients with heart failure and systolic dysfunction. (2011) (84)
Intracardiac, intravascular, two-dimensional, high-frequency ultrasound imaging of pulmonary artery and its branches in humans and animals. (1990) (84)
COMPUTED TOMOGRAPHY IN THE DIAGNOSIS OF PERICARDIAL HEART DISEASE (1982) (83)
In vitro analysis of mechanisms of balloon valvuloplasty of stenotic mitral valves. (1987) (83)
Weight changes after hospitalization for worsening heart failure and subsequent re-hospitalization and mortality in the EVEREST trial. (2009) (83)
HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction--pharmacological approaches. Heart Failure Society of America. (2000) (81)
Effect of amlodipine on the survival of patients with severe chronic heart failure due to a nonischemic cardiomyopathy: results of the PRAISE-2 study (prospective randomized amlodipine survival evaluation 2). (2013) (81)
The Hospital Readmission Reduction Program Is Associated With Fewer Readmissions, More Deaths: Time to Reconsider. (2017) (80)
Short-term Clinical Effects of Tolvaptan, an Oral Vasopressin Antagonist, in Patients Hospitalized for Heart Failure (2007) (79)
Predictive Value of Low Relative Lymphocyte Count in Patients Hospitalized for Heart Failure With Reduced Ejection Fraction: Insights from the EVEREST Trial (2012) (78)
Measuring and improving quality of care : A report from the american heart Association/American college of cardiology first scientific forum on assessment of healthcare quality in cardiovascular disease and stroke (2000) (77)
Ventricular remodeling in a mouse model of myocardial infarction. (1998) (76)
The prognostic significance of heart rate in patients hospitalized for heart failure with reduced ejection fraction in sinus rhythm: insights from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study With Tolvaptan) trial. (2013) (75)
Effects of Xanthine Oxidase Inhibition in Hyperuricemic Heart Failure Patients: The EXACT-HF Study (2015) (75)
Factors contributing to perforations resulting from laser coronary angioplasty: observations in an intact human postmortem preparation of intraoperative laser coronary angioplasty. (1985) (72)
Real-time intravascular ultrasound imaging in humans. (1990) (72)
Use of Equilibrium (Gated) Radionuclide Ventriculography to Quantitate Left Ventricular Output in Patients With and Without Left‐sided Valvular Regurgitation (1981) (70)
Acute Hemodynamic Effects of Conivaptan , a Dual V 1 A and V 2 Vasopressin Receptor Antagonist , in Patients With Advanced Heart Failure (2001) (69)
Effects of tolvaptan on dyspnoea relief from the EVEREST trials. (2009) (68)
The impact of chronic obstructive pulmonary disease in patients hospitalized for worsening heart failure with reduced ejection fraction: an analysis of the EVEREST Trial. (2012) (67)
Emerging ventricular assist devices for long-term cardiac support (2010) (66)
Efficacy of retrograde coronary sinus cardioplegia in patients undergoing myocardial revascularization: a prospective randomized trial. (1988) (66)
ACC 2015 Core Cardiovascular Training Statement (COCATS 4) (Revision of COCATS 3) (2015) (66)
Association of Arginine Vasopressin Levels With Outcomes and the Effect of V2 Blockade in Patients Hospitalized for Heart Failure With Reduced Ejection Fraction: Insights From the EVEREST Trial (2013) (65)
New concepts in post-infarction ventricular remodeling. (2003) (63)
Beneficial Effects of Pimobendan on Exercise Tolerance and Qualit of Life in Patients With Heart Failure: Results of a Multicenter Trial (1992) (63)
Erratum: 'Evaluating quality of care for patients with heart failure' (Circulation (2000) 101 (e122-e140)) (2000) (63)
A New Noninvasive Method for the Estimation of Peak dP/dt (1993) (63)
Should beta-blockers be given to patients with heart disease and peanut-induced anaphylaxis? A decision analysis. (2004) (62)
Relationship between clinical trial site enrollment with participant characteristics, protocol completion, and outcomes: insights from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) trial. (2013) (61)
"Systolic and diastolic dysfunction" in heart failure? Time for a new paradigm. (2003) (60)
Management of heart failure. I. Pharmacologic treatment. (1994) (59)
Effect of Praliciguat on Peak Rate of Oxygen Consumption in Patients With Heart Failure With Preserved Ejection Fraction: The CAPACITY HFpEF Randomized Clinical Trial. (2020) (59)
Divergent effects of angiotensin-converting enzyme inhibition and angiotensin II-receptor antagonism on myocardial cellular proliferation and collagen deposition after myocardial infarction in rats. (1998) (59)
Relation of serum uric acid levels and outcomes among patients hospitalized for worsening heart failure with reduced ejection fraction (from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan trial). (2014) (57)
Serum aldosterone is associated with mortality and re‐hospitalization in patients with reduced ejection fraction hospitalized for acute heart failure: analysis from the EVEREST trial (2013) (56)
Thrombus imaging in a primate model with antibodies specific for an external membrane protein of activated platelets. (1989) (55)
Phase III clinical trial end points in acute heart failure syndromes: a virtual roundtable with the Acute Heart Failure Syndromes International Working Group. (2009) (54)
Assessing the population burden from heart failure: need for sentinel population-based surveillance systems. (1999) (54)
Noninvasive assessment of left ventricular remodeling: concepts, techniques, and implications for clinical trials. (2002) (53)
The Relationship Between Sinoatrial Conduction Time and Sinus Cycle Length During Spontaneous Sinus Arrhythmia in Adults (1974) (53)
Hypoalbuminaemia and incident heart failure in older adults (2011) (52)
Effects of amlodipine on exercise tolerance, quality of life, and left ventricular function in patients with heart failure from left ventricular systolic dysfunction. (2000) (51)
Length of hospital stay and 30‐day readmission following heart failure hospitalization: insights from the EVEREST trial (2015) (51)
The Hospital Readmissions Reduction Program: Nationwide Perspectives and Recommendations. (2019) (50)
Reliability of ventricular remodeling as a surrogate for use in conjunction with clinical outcomes in heart failure. (2005) (50)
Ventricular remodeling and its prevention in the treatment of heart failure. (1998) (50)
Prognostic significance of serum total cholesterol and triglyceride levels in patients hospitalized for heart failure with reduced ejection fraction (from the EVEREST Trial). (2013) (49)
Enalapril treatment and hospitalization with atrial tachyarrhythmias in patients with left ventricular dysfunction. (2003) (47)
Changes in ventricular volume, wall thickness and wall stress during progression of left ventricular dysfunction. The SOLVD Investigators. (1993) (46)
Mechanical cardiac support 2000: current applications and future trial design: June 15-16, 2000 Bethesda, Maryland. (2001) (45)
Drug and Device Effects on Peak Oxygen Consumption, 6-Minute Walk Distance, and Natriuretic Peptides as Predictors of Therapeutic Effects on Mortality in Patients With Heart Failure and Reduced Ejection Fraction (2011) (44)
Data monitoring committees: Promoting best practices to address emerging challenges (2017) (44)
Comparison of losartan and captopril on heart failure-related outcomes and symptoms from the losartan heart failure survival study (ELITE II). (2005) (42)
Established and Emerging Roles of Biomarkers in Heart Failure Clinical Trials (2016) (42)
Acute detection of ST-elevation myocardial infarction missed on standard 12-Lead ECG with a novel 80-lead real-time digital body surface map: primary results from the multicenter OCCULT MI trial. (2009) (42)
Health-related quality of life in a multicenter randomized controlled comparison of telephonic disease management and automated home monitoring in patients recently hospitalized with heart failure: SPAN-CHF II trial. (2011) (42)
Home Monitoring Should Be the Central Element in an Effective Program of Heart Failure Disease Management (2012) (42)
Effect of amrinone on right ventricular function: predominance of afterload reduction. (1986) (41)
Effects of angiotensin II receptor blockade versus angiotensin-converting-enzyme inhibition on ventricular remodelling following myocardial infarction in the mouse. (2003) (41)
American Heart Association Atrial Fibrillation Research Summit: A Conference Report From the American Heart Association (2011) (41)
Gender-specific patterns of left ventricular and myocyte remodeling following myocardial infarction in mice deficient in the angiotensin II type 1a receptor. (2005) (41)
Changes in serum potassium levels during hospitalization in patients with worsening heart failure and reduced ejection fraction (from the EVEREST trial). (2015) (39)
Effect of Exercise on Erythrocyte Count and Blood Activity Concentration After Technetium‐99m In Vivo Red Blood Cell Labeling (1982) (39)
Hospital cost effect of a heart failure disease management program: the Specialized Primary and Networked Care in Heart Failure (SPAN-CHF) trial. (2006) (39)
Comparison of symptomatic and functional responses to vagus nerve stimulation in ANTHEM‐HF, INOVATE‐HF, and NECTAR‐HF (2020) (38)
Rationale and design of the EMPERIAL‐Preserved and EMPERIAL‐Reduced trials of empagliflozin in patients with chronic heart failure (2019) (38)
Effects of tolvaptan on physician-assessed symptoms and signs in patients hospitalized with acute heart failure syndromes: analysis from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan (EVEREST) trials. (2011) (37)
Ventricular assist device therapy normalizes inducible nitric oxide synthase expression and reduces cardiomyocyte apoptosis in the failing human heart. (2005) (37)
Laser myoplasty for hypertrophic cardiomyopathy. In vitro experience in human postmortem hearts and in vivo experience in a canine model (transarterial) and human patient (intraoperative). (1984) (37)
Ventricular remodeling fundamental to the progression (and regression) of heart failure. (2011) (37)
Right ventricular function in adults with pulmonary hypertension with and without atrial septal defect. (1983) (35)
Economic impact of beta blockade in heart failure. (2001) (35)
Effect of long-term enalapril therapy on neurohormones in patients with left ventricular dysfunction. SOLVD Investigators. (1995) (34)
Efficacy of oral tolvaptan in acute heart failure patients with hypotension and renal impairment (2012) (34)
Right Heart Failure (1994) (34)
Nitrate therapy for heart failure: benefits and strategies to overcome tolerance. (2013) (33)
Haemodynamic effects, safety, and pharmacokinetics of human stresscopin in heart failure with reduced ejection fraction † (2013) (33)
Effectiveness of preload reserve as a determinant of clinical status in patients with left ventricular systolic dysfunction. The SOLVD Investigators. (1992) (32)
Antithrombotic therapy in heart failure patients with and without atrial fibrillation: update and future challenges. (2016) (32)
Destination mechanical circulatory support: proposal for clinical standards. (2003) (31)
Heart failure disease management a sustainable energy source for the health care engine. (2010) (30)
Incident hyperkalemia may be an independent therapeutic target in low ejection fraction heart failure patients: insights from the HEAAL study. (2014) (30)
Impact of Autonomic Regulation Therapy in Patients with Heart Failure: ANTHEM-HFrEF Pivotal Study Design. (2019) (30)
Acute and long-term effects of the angiotensin-converting enzyme inhibitor, enalapril, on adrenergic activity and sensitivity during exercise in patients with left ventricular systolic dysfunction. (1997) (30)
Acute Kidney Function Declines in the Context of Decongestion in Acute Decompensated Heart Failure. (2020) (30)
Task force 8: training in heart failure endorsed by the Heart Failure Society of America. (2008) (29)
Mechanical cardiac support 2000: current applications and future trial design. June 15-16, 2000 Bethesda, Maryland. (2001) (29)
Vasopressin receptor blockade in patients with congestive heart failure: results from a placebo controlled, randomized study comparing the effects of tolvaptan, furosemide, and their combination (2002) (29)
Heart failure training: a call for an integrative, patient-focused approach to an emerging cardiology subspecialty. (2004) (28)
Rationale and Design of the ATHENA-HF Trial: Aldosterone Targeted Neurohormonal Combined With Natriuresis Therapy in Heart Failure. (2016) (28)
Foundation/American Heart Association Task Force on Practice Guidelines Heart Failure in Adults. A Report of the American College of Cardiology Focused Update: ACCF/AHA Guidelines for the Diagnosis and Management of (2009) (28)
Natriuretic peptides and cardiovascular events: more than a stretch. (2007) (28)
HFSA guidelines for the management of patients with heart failure due to left ventricular systolic dysfunction--pharmacological approaches. (2000) (28)
Improving clinical outcomes with drug treatment in heart failure: what have trials taught? (2003) (27)
Influence of donor cocaine use on outcome after cardiac transplantation: analysis of the United Network for Organ Sharing Thoracic Registry. (2008) (27)
Combined analysis of resting regional wall thickening and stress perfusion with electrocardiographic-gated technetium 99m-labeled sestamibi single-photon emission computed tomography: Prediction of stress defect reversibility (1997) (27)
Predicting adverse events during angiotensin receptor blocker treatment in heart failure: results from the HEAAL trial (2012) (27)
Comparison of the electrocardiographic and hemodynamic responses to ionic and nonionic radiocontrast media during left ventriculography: a randomized double-blind study. (1986) (27)
Continuous Aortic Flow Augmentation: A Pilot Study of Hemodynamic and Renal Responses to a Novel Percutaneous Intervention in Decompensated Heart Failure (2005) (27)
Effects of Long‐term Enalapril Therapy on Left Ventricular Diastolic Properties in Patients With Depressed Ejection Fraction (1993) (26)
Equilibrium (gated) radionuclide ejection fraction measurement in the pressure or volume overloaded right ventricle. Comparison of three methods. (1984) (26)
Increased visit-to-visit blood pressure variability is associated with worse cardiovascular outcomes in low ejection fraction heart failure patients: Insights from the HEAAL study. (2015) (26)
Comparison of histamine release effects of ionic and non-ionic radiographic contrast media. (1986) (26)
Comparison of survival and other complications after heart transplantation in patients taking amiodarone before surgery versus those not taking amiodarone. (2004) (25)
Current perspective on the cardiovascular effects of coxibs. (2002) (24)
Peripheral vascular endothelial function correlates with exercise capacity in cardiac transplant recipients. (2003) (24)
Standardized definitions for evaluation of heart failure therapies: scientific expert panel from the Heart Failure Collaboratory and Academic Research Consortium (2020) (24)
Intravascular and Intracardiac Ultrasound Imaging: Current Research and Future Directions (1990) (24)
Atrial fibrillation or flutter on initial electrocardiogram is associated with worse outcomes in patients admitted for worsening heart failure with reduced ejection fraction: findings from the EVEREST Trial. (2012) (24)
A device is not a drug. (2003) (24)
Real‐Time, Intracardiac, Two‐Dimensional Echocardiography (1991) (24)
Outcomes in patients with symptomatic cerebrovascular disease undergoing heart transplantation. (2011) (24)
The Academic Medical System: Reinvention to Survive the Revolution in Health Care. (2017) (24)
Serum Osmolality and Postdischarge Outcomes After Hospitalization for Heart Failure. (2016) (22)
Advanced heart failure and transplant cardiology: a subspecialty is born. (2009) (22)
Acute Hemodynamic Effects of Tolvaptan , a Vasopressin V 2 Receptor Blocker , in Patients With Symptomatic Heart Failure and Systolic Dysfunction An International , Multicenter , Randomized , Placebo-Controlled Trial (2008) (22)
Impact of chronic kidney disease and anemia on hospitalization expense in patients with left ventricular dysfunction. (2003) (21)
Tolvaptan in Patients Hospitalized With Acute Heart Failure: Rationale and Design of the TACTICS and the SECRET of CHF Trials (2015) (21)
Catheter-induced versus spontaneous spasm. Do these coronary bedfellows deserve to be estranged? (1985) (21)
Multistate Model to Predict Heart Failure Hospitalizations and All-Cause Mortality in Outpatients With Heart Failure With Reduced Ejection Fraction: Model Derivation and External Validation (2016) (21)
Intracardiac echocardiography during simulated aortic and mitral balloon valvuloplasty: in vivo experimental studies. (1992) (21)
Changes in Dyspnea Status During Hospitalization and Postdischarge Health-Related Quality of Life in Patients Hospitalized for Heart Failure: Findings From the EVEREST Trial (2016) (20)
Influence of documented history of coronary artery disease on outcomes in patients admitted for worsening heart failure with reduced ejection fraction in the EVEREST trial (2013) (20)
Early and late effects of high- versus low-dose angiotensin receptor blockade on renal function and outcomes in patients with chronic heart failure. (2015) (20)
Laser-assisted debridement of aortic valve calcium. (1985) (20)
Progression of Left-ventricular Dysfunction During Enalapril Therapy - Relationship With Neurohormonal Reactivation (1993) (20)
Regional Validation and Recalibration of Clinical Predictive Models for Patients With Acute Heart Failure (2017) (19)
Design of the Heart failure Endpoint evaluation of AII‐Antagonist Losartan (HEAAL) study in patients intolerant to ACE‐inhibitor (2008) (19)
Temporal Changes in Postdischarge Mortality Risk After Hospitalization for Heart Failure (from the EVEREST Trial). (2016) (18)
RELAX-AHF: rising from the doldrums in acute heart failure (2013) (18)
Heart failure in the lifetime of Musca domestica (the common housefly). (2013) (18)
Implantable Cardioverter-Defibrillators in Patients Hospitalized for Heart Failure With Chronically Reduced Left Ventricular Ejection Fraction (2010) (18)
Patterns of ventricular remodeling after myocardial infarction: clues toward linkage between mechanism and morbidity. (2008) (18)
Ventricular remodeling and the renin angiotensin aldosterone system. (2000) (18)
Contemporary Medical Options for Treating Patients With Heart Failure (2002) (18)
Role of angiotensin converting enzyme inhibitors in preventing left ventricular remodelling following myocardial infarction. (1995) (17)
Recent advances in the treatment of heart failure. (2002) (17)
Persistence of cardiovascular risk after rofecoxib discontinuation. (2010) (17)
Designs for mechanical circulatory support device studies. (2007) (17)
Treatment guidelines in heart failure. (1998) (17)
Effect of acute angiotensin converting enzyme inhibition on left ventricular diastolic filling in patients with congestive heart failure: Relation to right ventricular volume (1990) (17)
Aligning quality and payment for heart failure care: defining the challenges. (2003) (16)
Vasopressin receptor blockade with tolvaptan in chronic heart failure: differential effects in normonatremic and hyponatremic patients (2002) (16)
Transforming health care through the medical home: the example of heart failure. (2009) (16)
Prognostic value of monocyte count in patients hospitalized for heart failure with reduced ejection fraction (from the EVEREST Trial). (2012) (15)
Protective effects of retrograde compared with antegrade cardioplegia on right ventricular systolic and diastolic function during coronary bypass surgery. (1989) (15)
COCATS 4 Task Force 12: Training in Heart Failure. (2015) (15)
Fear of Coronavirus Disease 2019-An Emerging Cardiac Risk. (2020) (15)
Endothelin expression and the progression of heart failure: exemplifying the vagaries of therapeutic development. (2004) (15)
Marital adjustment in heart transplantation patients and their spouses: A longitudinal perspective (1998) (15)
Effects of afterload and preload on right ventricular systolic performance (1988) (14)
Prevention and reversal of left ventricular remodeling: summation. (2002) (14)
In-Hospital Diuretic Agent Use and Post-Discharge Clinical Outcomes in Patients Hospitalized for Worsening Heart Failure: Insights From the EVEREST Trial. (2016) (14)
Sisyphus and 30-Day Heart Failure Readmissions: Futility in Predicting a Flawed Outcome Metric. (2016) (14)
Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial. (2021) (14)
Congenital pericardial defect diagnosed by computed tomography. (1985) (13)
A Multicenter Randomized Controlled Comparison of Telephonic Disease Management vs. Automated Home Monitoring in Patients Recently Hospitalized with Heart Failure: Span-CHF II Trial (2005) (13)
Acute Hemodynamic Effects of Tolvaptan, a Vasopressin V2 Receptor Blocker, in Patients with Symptomatic Heart Failure and Systolic Dysfunction: The ECLIPSE International, Multicenter, Randomized, Placebo-controlled Trial (2007) (13)
Magnetic resonance imaging with gadolinium-DTPA for detecting cardiac transplant rejection in rats. (1988) (13)
Rationale and design for a multicenter, randomized, double-blind, placebo-controlled, phase 2 study evaluating the safety and efficacy of the soluble guanylate cyclase stimulator praliciguat over 12 weeks in patients with heart failure with preserved ejection fraction (CAPACITY HFpEF). (2020) (13)
Cause and management of heart failure in patients with chronic renal disease. (2001) (12)
Advanced heart failure and transplant cardiology: a subspecialty is born. (2009) (12)
Are drug-induced changes in left ventricular ejection fraction or volumes adequate surrogates for long-term natural history outcomes in heart failure? (1999) (12)
Prostaglandin mediation of hemodynamic responses to pulmonary microembolism in rabbits: effects of ibuprofen and meclofenamate. (1987) (12)
Newer mechanical devices in the management of acute heart failure (2007) (11)
Ergonovine Provocation in Post Partum Myocardial Infarction (1984) (11)
Experimental Observations on Intracavitary Imaging of Cardiac Structures with 20‐MHz Ultrasound Catheters (1991) (11)
Left ventricular inotropic effect of atrial pacing after coronary artery bypass grafting. (1989) (11)
ACE inhibitors after myocardial infarction. (1993) (11)
Effect of acute angiotensin converting enzyme inhibition on left ventricular filling in patients with congestive heart failure. Relation to right ventricular volumes. (1990) (10)
Transplantations: Implications of the Heart Transplantation Process for Rehabilitation Counselors (1992) (10)
The economic effect of a tertiary hospital-based heart failure program. (2005) (9)
Relation of serum magnesium levels and postdischarge outcomes in patients hospitalized for heart failure (from the EVEREST Trial). (2013) (9)
Gender does not affect postdischarge outcomes in patients hospitalized for worsening heart failure with reduced ejection fraction (from the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan [EVEREST] Trial). (2012) (9)
The Essential Role of Educator Development: 10 Years of the ACC Emerging Faculty Program. (2016) (9)
Kinetics of pulmonary platelet deposition and clearance during thrombin-induced microembolism in rabbits. (1989) (9)
Eff ects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure ( HEAAL study ) : a randomised , double-blind trial (2009) (9)
Intracardiac echocardiography: current developments (2005) (9)
Fear of Coronavirus Disease 2019-An Emerging Cardiac Risk. (2020) (9)
Assessment of Right Ventricular Function (1988) (8)
Dipyridamole thallium-201 imaging pre- and post-coronary angioplasty for assessment of regional myocardial ischemia in humans. (1989) (8)
Factors influencing exercise performance in patients with left ventricular dysfunction. SOLVD Investigators. Studies of Left Ventricular Dysfunction. (1998) (8)
Hyponatraemia and vasopressin in heart failure: markers or mediators? (2011) (8)
Colloid osmotic pressure: an under-recognized factor in the clinical syndrome of heart failure. (2003) (8)
Realtime intracardiac two-dimensional echocardiography in the catheterization laboratory in humans (1990) (8)
Mineralocorticoid receptor antagonist use in hospitalized patients with heart failure, reduced ejection fraction, and diabetes mellitus (from the EVEREST Trial). (2014) (8)
Renal function and heart failure treatment: when is a loss really a gain? (2011) (7)
Heart failure training: a call for an integrative, patient-focused approach to an emerging cardiology subspecialty (2004) (7)
Sustained Cognitive and Economic Benefits of Resistance Training Among Community- Dwelling Senior Women: A 1-Year Follow-up Study of the Brain Power Study (2010) (7)
Relation between therapy‐induced changes in natriuretic peptide levels and long‐term therapeutic effects on mortality in patients with heart failure and reduced ejection fraction (2016) (7)
Angiotensin converting enzyme inhibition in asymptomatic left ventricular systolic dysfunction and early heart failure. (1995) (7)
Hyperkalaemia in heart failure: binding the patient to improved treatment? (2015) (7)
The Right Ventricle (2011) (7)
Comment--Val-HeFT and angiotensin-receptor blockers in perspective: A tale of the blind man and the elephant. (2002) (7)
Sudden Death After Hospitalization for Heart Failure With Reduced Ejection Fraction (from the EVEREST Trial). (2018) (6)
Heart Failure With Preserved Ejection Fraction: What Is in a Name? (2015) (6)
Highlights of the 2004 scientific sessions of the Heart Failure Society of America, Toronto, Canada, September 12 to 15, 2004. (2005) (6)
Fatty infiltration of right ventricle (adipositas cordis): an unrecognized cause of early graft failure after cardiac transplantation. (2005) (6)
EARTH: EndothelinA Receptor Antagonist Trial in Heart Failure (2001) (6)
Mechanical circulatory support devices for acute heart failure syndromes: considerations for clinical trial design (2008) (6)
Antithrombotic therapy in heart failure: WATCHful wondering. (2009) (6)
Stress and Health-related Quality of Life Individuals Undergoing Cardiac Transplantation and their Spouses (1999) (5)
Standardized Definitions for Evaluation of Heart Failure Therapies: Scientific Expert Panel From the Heart Failure Collaboratory and Academic Research Consortium. (2020) (5)
Rationale and Design of the Aldosterone Targeted NeuroHormonal CombinEd with Natriuresis TherApy in Heart Failure (ATHENA-HF) Trial (2016) (5)
Challenges and Potential Improvements to Patient Access to Pharmaceuticals: Examples From Cardiology. (2020) (5)
Preload reserve a determinant of clinical status in patients with left ventricular systolic dysfunction (1991) (5)
Donor-specific transfusion and cardiac xenografts. (1988) (5)
Acute myocardial infarction, normal coronary arteries and catheter-induced spasm. (1986) (5)
787 Prognostic value and changes in renal function in patients admitted with acute heart failure - results from the EVEREST program (2008) (5)
Association of Volume Overload With Kidney Function Outcomes Among Patients With Heart Failure With Reduced Ejection Fraction (2020) (5)
Design of a "Lean" Case Report Form for Heart Failure Device Development. (2019) (5)
Utility of In Vivo, Intracardiac Two‐Dimensional Echocardiography in the Assessment of Myocardial Risk Area and Myocardial Dyssynergy During Coronary Occlusion and Reperfusion (1994) (5)
Dosing of losartan in men versus women with heart failure with reduced ejection fraction: the HEAAL trial (2021) (5)
Positive Affect: A Neglected Group Treatment Outcome Measure in Assessing Efficacy of Psychosocial Group Interventions in Individuals with Heart Failure (1999) (5)
Sunday, 26 August 2012 (2012) (5)
Effect of warfarin anticoagulation on survival in patients with left ventricular systolic dysfunction (1996) (5)
Pulmonary hypertension in systemic lupus erythematosus: Hemodynamics and effects of vasodilator therapy (1980) (5)
Effect of amiodipine on exercise tolerance and quality of life in mild-to-moderate heart failure with systolic dysfunction (1996) (4)
Current Controversies and Implications for Clinical Trials (2018) (4)
Whose Metric Is It, Anyway?: Time for Patients to Assert Quality Control. (2016) (4)
Seeking new heights in acute heart failure syndromes: lessons from ASCEND and EVEREST. (2013) (4)
Cardiovascular events and COX-2 inhibitors. (2001) (4)
Catheter fragmentation: a potential source of catheter embolus. (1983) (4)
State of the Science: The Relevance of Symptoms in Cardiovascular Disease and Research: A Scientific Statement From the American Heart Association (2022) (4)
Positive inotropic agents in congestive heart failure. (1993) (4)
Matters of the heart: assessing the cardiovascular safety of new drugs. (2003) (4)
A cost-saving strategy for inpatient management of advanced decompensated heart failure patients: the Cardiomyopathy Unit. (2009) (4)
President's page: an urgent call to action: graduate medical education funding and the future of health care. (2013) (4)
Percutaneous and intraoperative intracardiac echo-cardiography in humans with the use of a small size (6F), low-frequency (12.5 MHz) ultrasound catheter with expanded depth of field (1991) (4)
Intracardiac echocardiographic guidance and monitoring during aortic and mitral balloon valvuloplasty: In vivo experimental studies (1990) (4)
Digoxin Benefit Varies by Risk of Heart Failure Hospitalization: Applying the Tufts MC HF Risk Model. (2017) (4)
Nesiritide ASCENDs the ranks of unproven treatments for acute heart failure. (2012) (4)
Seeking therapeutic precision in heart failure: is ejection fraction really the way? Deconstructing the CHARM of heart failure with mid‐range ejection fraction (2018) (4)
Highlights of the 2003 scientific sessions of the Heart Failure Society of America; Las Vegas, Nevada, September 21 to 24, 2003. (2004) (3)
Magnetic resonance imaging in ischemic injury after heart transplantation in rats. (1991) (3)
Total lymphoid irradiation and discordant cardiac xenografts. (1990) (3)
Despair over disparities: challenges and pathways to "affordable care". (2011) (3)
For vaptans, as for life, balance is better (2020) (3)
Post‐discharge haemodilution, congestion, and clinical outcomes among patients hospitalized for heart failure with reduced ejection fraction: results from the EVEREST trial (2019) (3)
Relating quality of care to clinical outcomes in heart failure: in search of the missing link. (2001) (3)
Rates of In-hospital Decongestion and Association with Mortality and Cardiovascular Outcomes among Patients admitted for Acute Heart Failure. (2022) (3)
A Group Intervention for Cardiac Transplantation Recipients and Their Families (1995) (3)
Aspirin and heart failure: square evidence meets a round patient. (2003) (3)
Reversal of left ventricular remodeling by pericardial tamponade. (2005) (3)
The Decrease in Hospitalizations For Heart Failure During the Covid-19 Pandemic: A Community and Academic Hospital Comparison Study (2020) (3)
Quantitation of Aortic Regurgitation (1988) (3)
Developing a Program for Tracking Heart Failure (2000) (3)
Quantitation of left ventricular output in patients with and without left-sided valvular regurgitation using equilibrium radionuclide ventriculography (1981) (3)
The Heart Failure Society of America in 2020: a vision for the future. (2012) (3)
250 Mode of death and cardiovascular re‐hospitalization in patients admitted with acute heart failure ‐ results from the EVEREST program (2008) (3)
Coronary angioplasty and thrombolysis for acute myocardial infarction: is two a crowd? (1989) (3)
Scintigraphic diagnosis of tricuspid regurgitation. (1982) (3)
Monday, 27 August 2012 (2012) (3)
Force on Practice Guidelines, International Society for Heart and Lung American College of Cardiology Foundation/American Heart Association Task Management of Heart Failure in Adults 2009 Focused Update: ACCF/AHA Guidelines for the Diagnosis and (2009) (3)
Monday, 27 August 2012 (2012) (3)
Rates of Reversal of Volume Overload in Hospitalized Acute Heart Failure: Association With Long-term Kidney Function. (2021) (3)
Aberrant hepatic artery: A potential cause for error in the angiographic diagnosis of traumatic liver hematoma (1979) (3)
Effects of atrial cardioplegia on the ischemic right ventricle after acute coronary artery occlusion and reperfusion. (1989) (3)
Real World Data as Trial End Points: Off and Running With a Long Way to Go. (2020) (3)
Heart Failure Costs, Minority Populations, and Outcomes: Targeting Health Status, Not Utilization, to Bend the Cost-Effectiveness Curve. (2018) (3)
Acute Effect of the V2 Receptor Blocker, Tolvaptan, on Dyspnea in Patients Hospitalized with Heart Failure: Results of the SECRET of CHF (2016) (2)
Moderate renal insufficiency does not attenuate the clinical benefit of aldosterone antagonists in heart failure. (2012) (2)
Challenges for the Basis of Practice The Role of Digoxin in the Treatment of Heart Failure (2008) (2)
Heart failure with normal ejection fraction, heart failure with preserved ejection fraction, diastolic heart failure, or huff-puff: time for a new taxonomy for hypertensive-metabolic heart failure. (2014) (2)
Rationale, design, and methods for a pivotal randomized clinical trial of continuous aortic flow augmentation in patients with exacerbation of heart failure: the MOMENTUM trial. (2007) (2)
New trends in the interventional treatment of ischaemic heart disease. (1997) (2)
Digitalis Therapy for Congestive Heart Failure: Is the Jury Still Out? (1988) (2)
Comparison of Effects on Left Ventricular Ejection Fraction of Iopamidol and Renografin During Left Ventriculography and Coronary Arteriography (1984) (2)
Force on Practice Guidelines, International Society for Heart and Lung American College of Cardiology Foundation/American Heart Association Task Diagnosis and Management of Heart Failure in Adults 2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the (2009) (2)
Percutaneous continuous aortic flow augmentation for cardiac recovery in a chronic heart failure patient with peripheral vascular disease. (2006) (2)
Pharmacologic Treatment of Congestive Heart Failure-Reply (1995) (2)
Cardiovascular events and COX-2 inhibitors. Authors' reply (2001) (2)
A Multi-State Model to Predict Heart Failure Hospitalizations and All-Cause Mortality in Outpatients With Heart Failure (2015) (2)
Administration of captopril following MI reduced the incidence of ischemia-related events. (1998) (2)
Percutaneous mechanical devices in the management of decompensated heart failure (2007) (2)
Vagus Nerve Stimulation for Chronic Heart Failure: Differences in Therapy Delivery and Clinical Efficacy in ANTHEM-HF, INOVATE-HF, and NECTAR-HF (2019) (2)
Gun Violence and Cardiovascular Health. (2019) (2)
Baseline Predictors of Clinical Success During Randomized Assessment of Aortic Flow Therapy in Heart Failure Exacerbation Refractory to Pharmacological Therapy: Analysis of the Multi-center MOMENTUM Trial (2008) (2)
Key issues in trial design for ventricular assist devices: a position statement of the Heart Failure Society of America. (2004) (2)
Viability, Remodeling, and CABG: Another STICH in the Shroud of Observation-Based Paradigm? (2015) (2)
Long-term Effects of Enalapril On Left-ventricular Diastolic Properties - Evidence for Reversed Remodeling (1992) (2)
Angiotensin Receptor-Neprilysin Inhibition in Heart Failure With Reduced Ejection Fraction: A Paradigm for All? (2016) (2)
ACCF/AHA Practice Guideline: Focused Update Practice Guideline: Focused Update 2009 Focused Update: ACCF/AHA Guidelin s for the Diagnosis and Management of Heart Failure in Adults (2009) (2)
Advances in Our Clinical Understanding of Autonomic Regulation Therapy Using Vagal Nerve Stimulation in Patients Living With Heart Failure (2022) (2)
COPEPTIN LEVELS IN ACUTE HEART FAILURE ARE ASSOCIATED WITH A HIGHER RISK PHENOTYPE, BUT NOT DIURETIC RESPONSE (2020) (1)
355 Temporal changes in U.S. hospitalizations, costs and clinical characteristics of patients with severe acute decompensated heart failure (2005) (1)
Activities and Compensation of Advanced Heart Failure Specialists: Results of the Heart Failure Society of America (HFSA) Survey. (2015) (1)
Calcium channel blockers in heart failure: help or hindrance? (1996) (1)
Abstract 20769: Sudden Cardiac Death Risk After Hospitalization for Heart Failure: Insights From EVEREST (2017) (1)
Association of Preexisting Heart Failure With Outcomes in Older Patients With Diffuse Large B-Cell Lymphoma. (2023) (1)
A Longitudinal Study of Health-related Quality of Life in Recipients of Heart Transplantations (1997) (1)
Renal actions of the cancion® Cardiac Recovery System in severe experimental heart failure (2004) (1)
Flow cytometric analysis of platelet padgem expression during percutaneous transluminal coronary angioplasty (1991) (1)
Endothelial Function/Coronary Blood Flow/Coronary Artery Disease Syndromes (2005) (1)
EARLY AND LATE EFFECTS OF ANGIOTENSIN RECEPTOR BLOCKADE ON KIDNEY FUNCTION IN PATIENTS WITH CHRONIC HEART FAILURE (2012) (1)
Management of Ischemic Heart Disease: Therapeutic Options and Future Directions Official Satellite Symposium to the XVIIth Congress of the European Society of Cardiology (1998) (1)
When Is a Loss Really a Gain? (2011) (1)
177 European experience with the cancion cardiac recovery system (2004) (1)
Ventricular remodelling: an equal‐opportunity prognosticator (2020) (1)
Current concepts in the treatment of patients with heart failure (1998) (1)
Clinical Implications of the PR Interval in Patients Hospitalized for Worsening Heart Failure and Reduced Ejection Fraction: Analysis of The EVEREST Study (2014) (1)
The Battle for Enrollment: Preventing Collateral Damage on Clinical Trial Outcomes. (2021) (1)
THE FUTURE OF CARDIOVASCULAR CARE: FROM AFFORDABLE CARE TO THE ACADEMIC MEDICAL CENTER. (2018) (1)
Mining gold standards from ivory towers: quality of care in academic medical centers. (1999) (1)
246 Clinical implications of the QRS duration in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: Results from the EVEREST program (2008) (1)
FAILURE WRITING ON BEHALF OF THE 2005 HEART FAILURE WRITING GUIDELINE FOR THE MANAGEMENT OF PATIENTS WITH CHRONIC HEART (2009) (1)
Eosinophilic Myocarditis With Rapid Progression to Cardiogenic Shock, Managed With Mechanical Support and High-Dose Corticosteroids. (2018) (1)
Quality of care for patients with heart failure (2002) (1)
Chauges in Ventricular Volume, Wall Thickness and Wall Stress During Progression of Left Ventricular Dysfuncthu (2016) (1)
Novel neurohormonal antagonist strategies: vasopressin antagonism, anticytokine therapy, and endothelin antagonism in patients who have heart failure. (2005) (1)
Treatment of asymptomatic patients with left ventricular dysfunction. (1994) (1)
HFSA Working Group Designs for Mechanical Circulatory Support Device Studies (2007) (1)
Progression of left ventricular dysfunction in patients with heart failure. SOLVD Investigators. The Studies of Left Ventricular Dysfunction. (1993) (1)
Pre-transplant amiodarone exposure is associated with increased mortality following cardiac transplantation: an analysis of the united network for organ sharing thoracic registry (2003) (1)
1088-123 Cancion cardiac recovery system: Hemodynamic and renal effects (2004) (1)
DIURETIC DOSE AND OUTCOMES AMONG HOSPITALIZED HEART FAILURE PATIENTS: INSIGHTS FROM THE EVEREST TRIAL (2013) (1)
Abstract 12794: Hospital Length of Stay and Readmissions Post Heart Failure Hospitalization in the EVEREST Trial (2014) (1)
PLACEBO EFFECTS ON KANSAS CITY CARDIOMYOPATHY QUESTIONNAIRE SCORES IN PATIENTS WITH HEART FAILURE: A SYSTEMATIC REVIEW OF CONTEMPORARY RANDOMIZED CONTROLLED TRIALS (2022) (1)
Clinical Investigations Factors Influencing Exercise Performance in Patients With Left Ventricular Dysfunction (1998) (1)
Dosing of losartan in men vs. women with HFrEF: the HEAAL trial. (2021) (1)
Early Assessment and Treatment Acute Heart Failure Syndromes in Patients With Coronary Artery Disease (2009) (0)
PHARMACOLOGIC TREATMENT OF CONGESTIVE HEART FAILURE. AUTHORS' REPLY (1995) (0)
Heart Failure/Transplantation Cost-Effectiveness of Screening With B-Type Natriuretic Peptide to Identify Patients With Reduced Left Ventricular Ejection Fraction (2004) (0)
Abstract 20282: Comparative Estimates of Heart Failure Hospitalization Between Simple and Multi-State Proportional Hazard Models in a Population With a High Rate of Competing Events (2016) (0)
Special Report Research Priorities in Hypertrophic Cardiomyopathy Report of a Working Group of the National Heart, Lung, and Blood Institute Genetic Cause (2010) (0)
Current focus in treating and managing coronary artery disease and heart failure (1997) (0)
A Cost Saving Strategy for Hemodynamic Monitoring of Heart Failure Patients: The Cardiomyopathy Unit (2007) (0)
Role of beta-blocker therapy in the postmyocardial infarction patient with and without left ventricular dysfunction consensus guideline. (2003) (0)
High versus low dose losartan and serum potassium: an analysis from HEAAL. (2022) (0)
Comparison of Resting Scintigraphy With 201T1 and 99mTc-Sestamibi (2005) (0)
Contents Vol. 1, 2001 (2001) (0)
P3522Vagus nerve stimulation for chronic heart failure: differences in therapy delivery and clinical efficacy in ANTHEM-HF, INOVATE-HF, and NECTAR-HF (2019) (0)
Peripheral vascular endothelial function predicts exercise capacity in cardiac transplant recipients (2002) (0)
Predicting Adverse Effects during Angiotensin Receptor Blocker Treatment in Heart Failure: Results from the HEAAL Trial (2010) (0)
Abstract 2416: Progressive Improvement in Cardiac Performance produced by Continuous Aortic Flow Augmentation in Patients Hospitalized with Acute Decompensated Heart Failure: Results from the MOMENTUM Trial (2008) (0)
Abstract 16636: Superior Vena Caval Occlusion: A Novel Approach to Improve Cardiac Function in Heart Failure (2015) (0)
Challenges for the Basis of Practice Should We Use Outpatient Dobutamine or Milrinone (2009) (0)
INFLUENCE OF URIC ACID LEVEL IN PATIENTS HOSPITALIZED FOR HEART FAILURE WITH REDUCED EJECTION FRACTION: INSIGHTS FROM THE EVEREST TRIAL (2013) (0)
Abstract 13328: Coronary Artery Disease is Associated with a Poor Post-Discharge Prognosis in Patients Hospitalized for Heart Failure with Reduced Ejection Fraction: Findings from the EVEREST Trial (2011) (0)
267 Effects of tolvaptan on physician-assessed signs and symptoms in patients admitted with acute heart failure - results from the EVEREST program (2008) (0)
Acute Declines in Kidney Function in the Context of Decongestion in Patients with Acute Decompensated Heart Failure (2022) (0)
Barriers to Clinical Trial Efficiency: The Heart Failure Collaboratory Industry Experience (2019) (0)
Prediction of Long Term Mortality in Patients with Chronic Heart Failure Undergoing Angiotensin Receptor Blockade (2013) (0)
Trends in the utilization of implantable cardioverter defibrillator and amiodarone therapy in patients undergoing cardiac transplantation: an analysis of the united network for organ sharing thoracic registry (2003) (0)
New concepts of clinical practice guideline for heart failure (1998) (0)
The effect of tablet computer-based telemonitoring added to an established telephone disease management program on heart failure hospitalizations: The Specialized Primary and Networked Care in Heart Failure (SPAN-CHF) III Randomized Controlled Trial. (2023) (0)
Heart Failure Society of America: a society with a mission. (2002) (0)
Rapid Communication Intracardiac , Intravascular , Two-Dimensional , High-Frequency Ultrasound Imaging of Pulmonary Artery and Its Branches in Humans and Animals (2005) (0)
Clinical Practice Guidelines in Heart Failure: State of the Art in the United States (2000) (0)
Barriers to Clinical Trial Efficiency and Patient Access: The Heart Failure Collaboratory Industry Survey (2020) (0)
Subject Index Vol. 1, 2001 (2001) (0)
Regional Comparison of Baseline Therapy in Patients Hospitalized for Acute Heart Failure with Systolic Dysfunction (2007) (0)
Heart Failure: A Cardio-Renal-Vascular Syndrome (2008) (0)
Effects of Tolvaptan in Patients Hospitalized with Heart Failure and Renal Impairment and Hypotension in the EVEREST Trial (2008) (0)
Natriuretic Peptides and Cardiovascular Events (2016) (0)
Dilemmas With Race and Heart Failure Treatment. (2016) (0)
FRS-080 Clinical Results with the Orqis Medical Cancion CRS Therapy(Clinical Heart Failure, Diagnosis and Treatment-1 (M) FRS16,Featured Research Session (English),The 70th Anniversary Annual Scientific Meeting of the Japanese Circulation Society) (2006) (0)
Orqis® Cancion® Cardiac Recovery System: Hemodynamic Effects of a Novel Minimally–Invasive Approach to Cardio-renal Support in Severe Acute Heart Failure (2004) (0)
Chapter 45 – Antagonism of the Renin-Angiotensin-Aldosterone System in Heart Failure (2011) (0)
Affordable Care: More Than Just an Act. (2017) (0)
Performance of Heart Failure Clinical Prediction Models: A Systematic External Validation Study (2021) (0)
TheRelationship BetweenSinoatrial Conduction TimeandSinus CycleLengthDuringSpontaneous SinusArrhythmia inAdults (1974) (0)
Prevalent Heart Failure And Cardioprotective Medication Use In Older Individuals With Lymphoma: A SEER-Medicare Analysis (2022) (0)
55: Clinical and Hemodynamic Findings with a System for Delivery of Aortic Flow Therapy in Patients with Acute Decompensated Heart Failure (2009) (0)
Placebo Effects On Natriuretic Peptide Levels In Patients With Heart Failure: A Systematic Review Of Contemporary Randomized Controlled Trials (2022) (0)
Therapeutic Development Endothelin Expression and the Progression of Heart Failure : Exemplifying the Vagaries of (2004) (0)
Post-Discharge Adjudicated Outcomes in Patients with Implantable Cardioverter-Defibrillators in the EVEREST Trial (2008) (0)
SERUM MAGNESIUM LEVELS AND POSTDISCHARGE OUTCOMES IN PATIENTS HOSPITALIZED FOR HEART FAILURE: INSIGHTS FROM THE EVEREST TRIAL (2013) (0)
The Cardiovascular Pharmaceutical Cornucopia: A Conundrum of Riches. (2022) (0)
Short-Term Drug Effects on Hemodynamics as Predictors of Long-Term Therapeutic Effects on Mortality in Patients with Heart Failure and Left Ventricular Dysfunction (2013) (0)
385: Molecular recovery of the failing canine left ventricular myocardium following extended therapy with the Orqis Medical Cardiac Recovery System (2007) (0)
973-111 Improved Exercise Performance by Long-term Enalapril Treatment in Patients with First Anterior Myocardial Infarction: An One Year Follow-up Study (1995) (0)
High-dose versus low-dose losartan in patients with heart failure – Authors' reply (2010) (0)
281: Acute Left Ventricular Unloading in Dogs with Chronic Heart Failure: Comparison of Hemodynamics and Gene Expression between Intra-Aortic Balloon Counterpulsation and Continuous Aortic Flow Augmentation (2008) (0)
Antithrombotic Therapy in Heart Failure-The Clot Thickens. (2019) (0)
678 Hemodynamic Effects of Continuous Aortic Flow Augmentation in Patients Hospitalized With Acute Decompensated Heart Failure: Results from the MOMENTUM Trial (2008) (0)
Abstract 11413: Serum Aldosterone is Associated with Post-Discharge Events in Patients with Reduced Ejection Fraction Hospitalized for Heart Failure: Analysis from the Everest Trial (2011) (0)
Effects of Oral Tolvaptan on Left Ventricular Dilatation and Function in Patients with Heart Failure and Left Ventricular Systolic Dysfunction (2005) (0)
Economic Effect of a Tertiary ospital-Based Heart Failure Program (2016) (0)
Cancion® Cardiac Recovery System: Effects on Renal, Echocardiographic, and Health Status Parameters during and Following Treatment with a Novel, Minimally Invasive Approach to Cardio-Renal Support in Severe Acute Heart Failure (2004) (0)
The Journey Toward Advances in Diuretics Management: Quite Far and Not Far Enough. (2020) (0)
172 Cancion cardiac recovery system in severe heart failure: initial U.S. results of acute and sustained hemodynamic and clinical impact (2004) (0)
From the American Heart Association American Heart Association Atrial Fibrillation Research Summit: A Conference Report (2013) (0)
Ventricular Dysfunction Warfarin anticoagulation and survival: a cohort analysis from the Studies of Left (2011) (0)
Therapeutics Effects on 6-minute Walk Distance as a Predictor of Therapeutic Effects on Mortality in Heart Failure Randomized Trials (2010) (0)
Heart Association Forecasting the Impact of Heart Failure in the United States : A Policy Statement From the Print (2018) (0)
169: Effect of Intracorporeal Ventricular Assist Devices on the Risk of Mortality or Retransplantation Following Cardiac Transplantation – An Analysis of the United Network for Organ Sharing (UNOS) Registry (2008) (0)
Continuous aortic flow augmentation using the Orqis® CANCION® CRS™ therapy in patients with severe heart failure: Determinants of the hemodynamic response (2005) (0)
Lessons on the Patient Population for Device Trials in Heart Failure: Early Baseline Characteristics in the MOMENTUM Trial (2006) (0)
Comparative Effects of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blocking Agents on Left Ventricular Volumes in Elderly Patients with Heart Failure (1998) (0)
Reduction of Systemic Vascular Resistance Predicts a More Favorable Outcome in Patients with Severe Acute Decompensated Heart Failure: Insights from the MOMENTUM Trial (2008) (0)
President's page: The perfect storm part 2: a rally cry for medical research funding. (2013) (0)
INCIDENT HYPERKALEMIA IS AN INDEPENDENT THERAPEUTIC TARGET IN LOW EJECTION FRACTION HEART FAILURE PATIENTS. INSIGHTS FROM THE HEAAL STUDY (2012) (0)
PROGNOSTIC ROLE OF HEMOCONCENTRATION IN PATIENTS HOSPITALIZED FOR HEART FAILURE WITH REDUCED EJECTION FRACTION: AN ANALYSIS OF THE EVEREST TRIAL (2013) (0)
MINERALOCORTICOID RECEPTOR ANTAGONISTS IN DIABETIC PATIENTS HOSPITALIZED WITH HEART FAILURE: INSIGHTS FROM THE EVEREST TRIAL (2013) (0)
EVEREST: Modest Gains from Tolvaptan in Heart Failure (2007) (0)
Abstract 3015: Drug and Device Effects on Peak Oxygen Consumption as a Predictor of Therapeutic Effects on Mortality in Heart Failure Randomized Trials (2009) (0)
Abstract 2097: Acute Ventricular Unloading in Dogs with Chronic Heart Failure: Comparison Between Intra-Aortic Balloon Counterpulsation and Continuous Aortic Flow Augmentation (2007) (0)
Clinical results with the Orqis® medical cancion® CRS therapy (2005) (0)
Treatment of Remodeling: Inhibition of the Renin–Angiotensin–Aldosterone System (2005) (0)
Correlation of Ejection Fraction to Early Post-Discharge Sudden Death and All-Cause Mortality in The EVEREST Trial (2008) (0)
Regional Differences in Baseline Characteristics and Outcomes in Patients Hospitalized with Worsening Heart Failure and Systolic Dysfunction (2007) (0)
HFSA 2006 Comprehensive Heart Failure Practice Guideline HFSA 2006 Comprehensive Heart Failure Practice Guideline (2006) (0)
Comparison of patient data to computer simulation in an arterial cardiac assist device therapy of CHF suggests delayed recruited benefit in addition to immediate direct hemodynamic benefit (2004) (0)
Autonomic dysregulation in diabetes: CAN we prevent heart failure? (2022) (0)
The QRS Interval Predicts Mortality and Re-Hospitalization in Patients Hospitalized with Worsening Heart Failure and Systolic Dysfunction (2007) (0)
A symposium : current focus in treating and managing coronary artery disease and heart failure (1997) (0)
Effect of transplant center experience on post-transplant mortality for patients supported with an implantable left ventricular assist device: an analysis of the united network for organ sharing (UNOS) thoracic registry (2004) (0)
Abstract 13559: Gender Does Not Impact Post-Discharge Outcomes in Patients Hospitalized for Worsening Heart Failure with Reduced Ejection Fraction in the EVEREST Trial (2011) (0)
Pulmonary hypertension in systemic lupus erythematosus: hemodynamics and effects of vasodilator therapy: Pulmonary hypertension in SLE (1980) (0)
Are observation periods necessary during initiation and uptitration of carvedilol in heart failure patients (1999) (0)
Safety and Efficacy of the Soluble Guanylate Cyclase Stimulator Praliciguat in Patients with Heart Failure with Preserved Ejection Fraction (Capacity HFpEF): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial (2020) (0)
Initial clinical experience with the cancion ™ cardiac recovery system (2003) (0)
Reply: Chronic Kidney Disease Contributing to Dyspnea in Patients With Heart Failure. (2017) (0)
Abstract 13323: Chronic Obstructive Pulmonary Disease is Associated with Adverse Events in Patients Hospitalized for Heart Failure with Reduced Ejection Fraction: An Analysis of the EVEREST Trial (2011) (0)
Assessment of plasma tissue factor activity in patients presenting with coronary artery disease: limitations of a commercial assay (2009) (0)
Abstract 12797: Temporal Changes in Mortality Risk Post-Discharge After Hospitalization for Heart Failure (2014) (0)
Group of the National Heart, Lung, and Blood Institute Research Priorities in Hypertrophic Cardiomyopathy : Report of a Working (2011) (0)
Wednesday, 29 August 2012 (2012) (0)
Drug and Device Effects on Short Term Markers as Predictors of Long Term Therapeutic Effect on Mortality and Hospitalization for Heart Failure in Patients With Heart Failure and Reduced Ejection Fraction (2012) (0)
THE IMPACT OF GLUCAGON LIKE PEPTIDE-1 AGONIST THERAPY ON HEART RATE IN ADVANCED SYSTOLIC HEART FAILURE: AN ANALYSIS FROM THE FUNCTIONAL IMPACT OF GLP-1 FOR HEART FAILURE TREATMENT STUDY (2017) (0)
35 Regional differences in baseline characteristics and outcomes in patients admitted with acute heart failure - results from the EVEREST program (2008) (0)
Does Home Monitoring Heart Failure Care Improve Patient Outcomes? Home Monitoring Should Be the Central Element in an Effective Program of Heart Failure Disease Management C ONTROVERSIES IN C ARDIOVASCULAR M EDICINE (2012) (0)
rats Changes in pulmonary blood flow affect vascular response to chronic hypoxia in (2011) (0)
Effects of Ibopamine On Plasma Neuro-hormones and Symptoms in Heart-failure Patients Treated With Angiotensin-converting Enzyme-inhibitors (1994) (0)
Comparison of the Early (1995–1998) and Late (1999–2001) Experience with the use of Implantable Left Ventricular Assist Devices on Post-Transplant Mortality: An Analysis of the United Network for Organ Sharing (UNOS) Thoracic Registry (2004) (0)
Prognostic importance of a wide QRS complex in asymptomatic patients with depressed left ventricular function in predicting mortality (2002) (0)
Abstract 12884: Arginine Vasopressin Levels Predict Post-Discharge Morbidity and Mortality in Patients Admitted for Worsening Heart Failure With Reduced Ejection Fraction: Insights From the EVEREST Trial (2011) (0)
Some Thoughts from Your Publisher (2001) (0)
High- versus low-dose losartan and uric acid: An analysis from HEAAL. (2023) (0)
Symposium summary remarks. (1997) (0)
Thirty‐day readmissions: Notes from the primordial era of health care metrics (2018) (0)
Utilization and Infection Rates Associated with Pulmonary Artery Catheter Monitoring in an Intermediate Care Environment (2006) (0)
The Role of Vasopressin and Vasopressin Antagonists in Heart Failure (2007) (0)
248 Use of a Propensity Score to Examine Association between Rates of In-Hospital Decongestion and Mortality and Cardiovascular Outcomes Among Patients admitted for Acute Heart Failure (2022) (0)
T083: The Effect of Heart Failure on Management and Outcomes of Older Patients with Hodgkin Lymphoma (2022) (0)
Exploring Ejection Fraction Range in Heart Failure Clinical Trials: Aid or Distraction for Personalized Treatment? (2023) (0)
right ventricular function: predominance of afterload reduction (2005) (0)
Use of a Propensity Score to Examine Association between Rates of In-Hospital Decongestion and Mortality and Cardiovascular Outcomes Among Patients admitted for Acute Heart Failure (2022) (0)
Identification of ischemic myocardium with rest reinjection of thallium201 following dipyridamole stress-redistribution imaging (1991) (0)
174 Hemodynamic unloading of the failing left ventricle with a single femoral extracorporeal dual‐lumen flow circuit (2004) (0)
Association of Therapeutic Effect on Functional and Physiological Markers and Change in Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction (2014) (0)
Does left ventricular assist device implantation volume affect post-cardiac transplant outcome? an analysis of the united network for organ sharing (UNOS) thoracic registry (2004) (0)
40: Changes In the Neurohormonal Profile of Patients Hospitalized for Acute Heart Failure Syndromes During the Early Post-Discharge Period According to Early, Late, or No Heart Failure Re-Hospitalization or Mortality Events: Analysis From the EVEREST Trials (2010) (0)
Toward Linkage Between Mechanism and Morbidity Patterns of Ventricular Remodeling After Myocardial Infarction: Clues (2009) (0)
Heart failure practice guidelines: guidance, not proscription. (1995) (0)
Placebo Effects On 6-minute Walk Test And Peak Oxygen Consumption In Patients With Heart Failure: A Systematic Review Of Contemporary Randomized Controlled Trials (2022) (0)
Aha Conference Proceedings American Heart Association Atrial Fibrillation Research Summit a Conference Report from the American Heart Association Mechanisms of Af: Basic and Translational Science and Genetics (2011) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Marvin A. Konstam?

Marvin A. Konstam is affiliated with the following schools: